Introduction
The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) has not been well established. Current guidelines recommend the combination of aspirin and an adenosine diphosphate (ADP) receptor antagonist for at least 12 months following myocardial infarction, including those patients managed with PCI. 1 DAPT in this context prevents stent thrombosis and other ischaemic events, but is associated with an increased risk of bleeding. [2] [3] [4] [5] In contemporary practice, DAPT is often discontinued prior to the guideline recommended duration of 12 months. [6] [7] [8] A growing body of evidence now supports the notion that a shortened duration of DAPT of 3-6 months may be sufficient to prevent stent thrombosis in elective PCI patients, particularly with newer generation stents. 3, [9] [10] [11] In contrast, the recent DAPT and Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS) trials demonstrated that the use of DAPT beyond 12 months following PCI or acute myocardial infarction (AMI) was associated with reduced major adverse cardiovascular events, albeit with increased bleeding. 12, 13 These studies suggest that the optimal duration of DAPT may be largely dependent on patient characteristics, index event, and procedural details. The added complexity of the decision-making process may translate to increased variability in practice patterns amongst treating physicians and deviation from guideline recommendations. In the present retrospective cohort study, we used contemporary registry data to examine real-world practice patterns, patient characteristics, and clinical outcomes following PCI for AMI in relation to DAPT duration.
Methods
The Canadian Observational Antiplatelet Study (COAPT) was a prospective, multicentre, longitudinal observational study examining ADP-receptor antagonist use following PCI for AMI. Patients 18 years of age undergoing PCI during their index admission for non-ST segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI) were included and followed for 15 months. Patients who did not receive an ADP-receptor antagonist or were enrolled in a clinical trial mandating specific antiplatelet or anticoagulation therapy as part of the trial protocol were excluded. Initiation, maintenance, and changes to treatment were solely at the discretion of the treating physician and the patient. The target enrollment was 2200 consecutive AMI patients treated in PCI-capable hospitals in Canada. All 43 PCI-capable hospitals across Canada were invited, and 26 sites participated in COAPT. The study was approved by institutional research ethics boards and all patients provided informed consent prior to participation. The primary objective of COAPT was to examine real-world practice patterns of DAPT use following PCI for AMI, and their association with patient and treatment characteristics. Secondary objectives included an assessment of the incidence of adverse events including death, myocardial infarction, ischaemic stroke, unplanned coronary revascularization, stent thrombosis, and bleeding events in relation to the type and duration of ADP-receptor antagonist therapy.
In the current analysis, we compared practice patterns, patient characteristics, and clinical outcomes in relation to the duration of DAPT following PCI for AMI. We stratified patients a priori into four DAPT duration intervals (<6 weeks, 6 weeks to <6 months, 6 to<12 months, and 12 months), and examined baseline patient characteristics, treatment variables, and adverse events within each stratum. The timing of DAPT discontinuation was coded independently from the reason for discontinuation, which may have included discontinuation as a result of death or a bleeding event. The primary cardiovascular outcome of the present analysis was the composite of non-fatal myocardial infarction, unplanned coronary revascularization, stent thrombosis, new or worsening heart failure, cardiogenic shock, or ischaemic stroke at 15 months. The composite cardiovascular outcome consisted of non-fatal events only to avoid confounding by reverse causation (i.e. patients classified as having discontinued DAPT early as a result of death). Secondary outcomes included death and bleeding events (any bleeding and bleeding as defined by the Bleeding Academic Research Consortium). 14 We present continuous variables using medians and interquartile ranges, and categorical variables using percentages or frequencies. We compared continuous variables using the Kruskal-Wallis test, and categorical variables using the v 2 test, or Fisher's exact test when appropriate. Trends were compared using the Jonckheere-Terpstra or the Cochran-Armitage trend tests where appropriate. We provided odds ratios and 95% confidence intervals (CI) for all endpoints analysed. Due to the non-randomized nature of this analysis, the independent association between DAPT duration and the composite cardiovascular outcome was examined using three main models, which included: (i) a complete-case propensity score adjusted analysis, (ii) a complete-case adjusted multilevel logistic regression analysis, and (iii) a multiple imputed adjusted regression model. Explanatory variables in the first and second models included duration of DAPT, age, systolic blood pressure, heart rate, type of myocardial infarction (STEMI vs. NSTEMI), oral anticoagulant (OAC) therapy on discharge, cardiac arrest on presentation, and previous history of myocardial infarction, PCI, heart failure, stroke, or transient ischaemic attack, atrial fibrillation, coronary artery bypass grafting, hypertension, and dyslipidemia. In the third model, we examined the association between key patient and treatment variables (including those for which only <95% of the data were available) and the odds of the composite cardiovascular outcome. Explanatory variables in this model included duration of DAPT (12 months compared with <6 weeks, 6 weeks to <6 months, and 6 to <12 months), GRACE risk score (a validated predictor of in-hospital mortality), 15 type of MI (STEMI vs.
NSTEMI), treatment with OAC on discharge, newer ADP-receptor antagonist (ticagrelor or prasugrel vs. clopidogrel), and the composite of a previous history of PCI, MI, or CABG.
The propensity score adjusted analysis (Model 1) was performed using marginal mean weighting through stratification (MMWS). The MMWS was obtained by combining elements of two propensity score-based techniques: stratification and weighting. 16 Multinomial logistic regression was used to estimate the propensity scores, with four propensity scores estimated for each patient. The region of common support was assessed to ensure that the resulting propensity scores were within the common bound of minimum and maximum ranges. Propensity scores were subsequently stratified into five similarly sized quintiles per stratum in each DAPT duration group. MMWS was then calculated in each stratum and DAPT duration group. Data balance was assessed by adjusting with MMWS weights. A total of 1895 of 2034 patients were analysed in the propensity score model as: (i) there were 44 patients with no propensity score and (ii) 95 patients had propensity scores outside the common region of support. We provide two adjusted estimates of the composite cardiovascular outcome: the first adjustment was obtained using MMWS as weights only, and the second was further adjusted by introducing additional covariates (used to construct the propensity score) to create a 'doubly robust model'. 16 In the second analysis (Model 2), we examined the odds of the composite cardiovascular outcome in relation to the duration of DAPT after adjusting for baseline differences in variables potentially associated with the timing of DAPT discontinuation and for which >95% of the data were available (complete case analysis). A multilevel random intercept model design was used to adjust for variability related to practice patterns in individual participating sites. The intraclass correlation coefficient was determined using an unconditional model with no predictor through PROC GLIMMIX in SAS.
The third analysis (Model 3) also included variables for which only <95% of the data might have been available. In this model, GRACE risk score was unavailable in 30% of patients. Multiple imputation was used to address missing data in the model under the assumption that data were missing at random. A SAS default single Markov chain Monte Carlo method, which assumes multivariate normality, was used to generate 20 complete datasets. All explanatory variables and the composite cardiovascular outcome were used as auxiliary variables when imputing missing data. The results of the complete models were combined (PROC MIANALYZE in SAS) to generate inferences. In an exploratory analysis, we included DAPT duration as a continuous variable, rather than a categorical variable, in Models 2 and 3.
Statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). Two-sided P values <0.05 were considered as statistically significant.
Results
Of the initial enrolment target of 2200 patients, 2179 patients were enrolled in 26 Canadian PCI-capable hospitals between December 2011 and May 2013. Of these 2179 patients, 2034 were included in this analysis as they had been started on DAPT following PCI for AMI and survived to hospital discharge. Upon discharge, clopidogrel was used in 72% of patients, ticagrelor in 17%, and prasugrel in 11%. DAPT duration was 12 months in 1531 patients (75.3%), 6 to <12 months in 256 (12.6%), 6 weeks to <6 months 142 (7.0%), and <6 weeks in 105 (5.2%).
Baseline patient characteristics stratified by duration of DAPT are summarized in Table 1 . In comparison to patients who continued DAPT 12 months, patients who received a shorter duration of DAPT were older, had higher creatinine levels, and a higher prevalence of atrial fibrillation, prior myocardial infarction, PCI, heart failure, and stroke or transient ischaemic attack. Table 2 outlines the characteristics and treatment of the index AMI. Compared with patients who received DAPT for 12 months, patients who received a shorter duration of DAPT were at higher baseline risk as evidenced by their higher GRACE risk scores, less likely to have received a drug-eluting stent, and more likely to be on an OAC upon discharge. Treatment characteristics were otherwise well balanced between DAPT duration strata. Data regarding reason for early DAPT discontinuation (defined as <12 months) were available for 325 patients (65%). Among these patients, the most common reasons for early discontinuation of DAPT were DAPT being deemed unneeded (49.5%) and other physician preference (29.5%). DAPT was discontinued early due to adverse events in 7.0% of patients, need for oral anticoagulation in 2.5%, need for surgery in 2.5%, patient preference in 3.1%, and financial constraints in 1.2%. Table 3 and Figure 1 illustrate the unadjusted ischaemic and safety outcomes in the overall population and after stratification by the duration of DAPT. Mortality rate at 15 months in the overall cohort was 2.5%: 21% in patients treated with DAPT <6 weeks, 11% in those treated for 6 weeks to <6 months, 3.1% for those treated for 6 to <12 months, and 0.3% in patients treated for 12 months. The composite cardiovascular outcome occurred in 16.6% of patients, non-fatal myocardial infarction in 9.4%, and stent thrombosis in 1.6%. There was a significant association between a shorter duration of DAPT and increased rates of these adverse events. With regard to ischaemic outcomes specifically, the rates of myocardial infarction and unplanned coronary revascularization correlated inversely with the duration of DAPT. In contrast, the rate of stent thrombosis was comparable in patients who received DAPT for 6 weeks (1.3%), and significantly higher in patients who received DAPT for <6 weeks (5.7%). There was also a significant association between longer duration of DAPT and reduced rates of new or worsening heart failure and cardiogenic shock. While the rates of any bleeding and need for blood transfusions were similar between DAPT duration strata, there was an inverse relationship between the incidence of BARC 2 bleeding and duration of DAPT.
The results of the propensity score analysis (Model 1) are summarized in Table 4 . In addition, all variables included as covariates in the propensity score and their respective adjusted odds ratios are listed in Supplementary material online, Table S1 . Shortened DAPT durations of <6 weeks and 6 weeks to < 6 months were associated with increased odds of the composite cardiovascular outcome compared with a duration of 12 months. Compared with a duration of 12 months, discontinuation of DAPT between 6 and <12 months was associated with a non-significant trend towards increased odds of the composite cardiovascular outcome. Additional covariates independently associated with an increased incidence of the composite cardiovascular outcome included prescription of an oral anticoagulant on discharge and a previous history of heart failure, stroke, or transient ischaemic attack (see Supplementary material online, Table S1 ).
The results of the multivariable logistic regression analyses (Models 2 and 3) are summarized in Supplementary material online, Tables S2 and S3. In Model 2, which used a multilevel random intercept model design to account for variability in practice patterns in individual sites, the intraclass correlation coefficient was 0.44 for the composite cardiovascular outcome. Compared with a DAPT duration 12 months, a shortened duration of DAPT of <6 weeks and 6 weeks to <6 months were independently associated with increased odds of composite cardiovascular outcome in both models. Additional variables independently associated with increased odds of the composite cardiovascular outcome included GRACE risk score, OAC on discharge, use of clopidogrel (vs. ticagrelor or prasugrel), and a the previous history of MI, PCI, and/or CABG. (see Supplementary material online, Table S3 
Discussion
The present study provides valuable insight into the contemporary use of DAPT following PCI for AMI. Current ACC/AHA guidelines recommend continuing DAPT for 12 months following ACS. 1 Although the majority of patients received DAPT for the guideline recommended duration of 12 months, early discontinuation of DAPT occurred in approximately 25% of patients. Patients in whom DAPT was discontinued <12 months after PCI were older and had higher risk profiles at baseline. There was an inverse correlation between the duration of DAPT following PCI and the rates of non-fatal ischaemic cardiovascular events, including myocardial infarction and unplanned coronary revascularization. While this was also true for stent thrombosis, the rates of stent thrombosis did not seem to vary significantly when duration of DAPT was 6 weeks. The overall rates of bleeding were comparable between DAPT duration cohorts, but the incidence of more significant clinical bleeding (BARC 2) had a paradoxical inverse correlation with the duration of DAPT-likely the result of confounding by reverse causation (i.e. DAPT discontinuation due to a bleeding event).
Although randomized controlled trials of ADP-receptor antagonists generally used a 12-month DAPT protocol, the duration of DAPT in these trials was arguably arbitrary. 2, 4, 5 The totality of the evidence regarding the optimal duration of DAPT following PCI for ACS remains inconclusive. [3] [4] [5] 17 Observational evidence does suggest that non-adherence to DAPT during the early post-PCI period is associated with an increased risk of adverse cardiovascular events, including stent thrombosis. 6, 7 However, recent studies have demonstrated that the actual minimum duration of DAPT required to reliably ensure the viability of a newly deployed stent may be shorter than previously estimated, and significantly shorter than the guideline recommended duration of 12 months following PCI. 3,9-11 The effect of shorter duration of DAPT in patients undergoing PCI in the context of ACS is uncertain, as the derived benefit may not only relate to the viability of a recently deployed stent. Two recent large randomized controlled trials suggest that prolonged DAPT following PCI, including patients post-ACS, reduces the incidence of stent thrombosis but increases bleeding; hence, the net clinical benefit of prolonged DAPT remains an area of active research and debate. 12, 18 In real-world practice, a prolonged duration of DAPT may be constrained by side effects, bleeding risks (particularly in patients with an indication for OAC), financial limitations, and complications of polypharmacy (including non-adherence). 8, [19] [20] [21] In addition, with the advent of newer generation stents, the rates of stent thrombosis, and other ischaemic events have decreased significantly; thus, previous recommendations regarding the optimal duration of DAPT following PCI may need to be revisited. 22, 23 In our contemporary cohort of AMI patients undergoing PCI, one in four discontinued DAPT before the guideline recommended duration of 12 months. Most importantly, in the vast majority of cases, DAPT was discontinued due to physician preference, rather than as a result of adverse events, need for surgery, or use of OAC. The proportion of physicians discontinuing DAPT due to the perception that it was no longer needed rose sharply after 6 months of DAPT-from 28 to 64% when discontinuation was <6 weeks vs. 6-12 months following PCI, respectively. These findings support the notion that there may be significant uncertainty among practicing physicians regarding the recommended and/or optimal duration of DAPT following myocardial infarction and PCI. Perceived lack of supporting evidence or clinical need for guideline-recommended practices by treating physicians has been previously identified as one of the most common reasons for not prescribing evidence-based therapies. 24 Our analysis corroborated the findings of previous observational studies demonstrating an inverse correlation between DAPT duration and adverse cardiovascular events. 6, 7 However, patients in whom DAPT was discontinued early represented a higher risk population at baseline; the exact effect of this bias on the differential rates of adverse events is difficult to ascertain. Interestingly, while the inverse correlation between adverse cardiovascular events and DAPT duration persisted across DAPT duration strata, the rate of stent thrombosis did not differ significantly as long as DAPT duration was 6 weeks. After this treatment period, the observed association between early DAPT discontinuation and increased adverse events may not relate to the viability of a newly deployed stent. After adjusting for potential confounders, an association between early DAPT discontinuation and increased adverse cardiovascular events was noted in patients discontinuing DAPT within 6 months of PCI. There was a trend towards an increased incidence of adverse events when DAPT was discontinued between 6 and <12 months, compared with discontinuation after 12 months, but it did not reach statistical significance. Although the current analysis represents a non-randomized comparison, our results would suggest that patients undergoing PCI for AMI in the current era benefit from completion of the guidelinerecommended 12-month DAPT course. 1 In addition, the comparable rates of stent thrombosis when DAPT duration was 6 weeks support previous observations that shorter durations of DAPT are sufficient to ensure viability of newer generation stents, and that the benefit derived from more prolonged DAPT may not relate to complications of a recently deployed stent. 
Limitations
The current study represents a non-randomized comparison designed to assess whether findings of large DAPT trials are reflected in 'realworld' practice. When assessing the effect of DAPT discontinuation, patients in whom DAPT was discontinued early represent a selected population as evidenced by differences in baseline characteristics between DAPT duration strata. We used multivariable logistic regression and propensity score MMWS analyses to adjust for variables potentially associated with the decision to discontinue DAPT. However, due to the non-randomized nature of this analysis, the residual effect of these variables and other unmeasured confounders cannot be completely corrected, and their exact effect on the observed clinical outcomes is difficult to ascertain. In the ancillary analysis using multiple imputation, data were assumed to be missing at random; however, the exact missing data mechanisms were not known and the assumption of data missing at random could not be verified. When assessing mortality and bleeding specifically, our observations are confounded by reverse causalitywhere DAPT would have been discontinued following death or a bleeding event. The effect of reverse causality is apparent in the strong inverse correlation between death and DAPT duration, and the paradoxical inverse correlation between duration of DAPT and BARC 2 bleeding. Thus, a causal relationship between early DAPT discontinuation and the incidence of these clinical outcomes should not be inferred. When examining DAPT discontinuation, the exact reason for early discontinuation was not provided for all patients. In addition, the specific type or the generation of drug-eluting stent was not recorded and might be associated with both the timing of DAPT discontinuation and clinical outcomes. Lastly, COAPT was not designed or powered to examine clinical outcomes in relation to DAPT duration following PCI for AMI. Despite these limitations, the present observational study provides valuable contemporary insights into the demographics, treatment, and outcomes of 'real-world' patients treated with DAPT following PCI for AMI.
Conclusion
In contemporary practice, the majority of patients undergoing PCI for AMI receive DAPT for at least 12 months. However, early discontinuation of DAPT is not uncommon and occurred in 25% of patients; more often due to physician preference rather than adverse events or need for surgical interventions. Patients at higher baseline risk are more likely to discontinue DAPT early, and early DAPT discontinuation is associated with increased rates of ischaemic events.
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